Home > Market Research > Prescription Medicines > Zydus Cadila Generics Company Intelligence Report

Table of Contents

Management Report
Published: March 2009
Pages: 14
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 195.00   Buy Now!
Research from: Espicom
Sector: Prescription Medicines

Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.

Cadila was founded in 1952, and was restructured in 1992 to become the Zydus Cadila Group. Cadila Healthcare, the Group's flagship company, was launched as an IPO in February 2000. The Zydus Group is aiming to become one of the top three healthcare companies in India and a global player. It has made forays into the US and EU markets, and other markets, such as Brazil, South Africa and Algeria. It started selling in Japan in 2007.

In July 2003, Zydus signed an agreement to acquire Alpharma SAS France, which it has renamed Zydus France. The acquisition gave the company an established distribution network and a pipeline of 109 generic registrations.

Zydus gained its first US ANDA approval, for atenolol tablets, in January 2005. The company has continued to push its presence in the US market since.

In May 2008, Zydus purchased the Spanish firm, Laboratorios Combix. The purchase enabled Zydus’ entry into the Spanish generics market. In November 2008, the firm acquired Etna Biotech in Italy, giving it a development platform for new vaccines.

Top of Page

Table of Contents

1.Executive Summary 2.Introduction 3.Products 4.Financial Results 5.Major Developments 6.Contact Details

For full details, please email keithw@cmsinfo.com

Top of Page

Buy now!

PDF single user

 GBP 195.00   

Online Access (1-user)

 GBP 195.00   

Paper

 GBP 195.00   

Your personal guarantee

Top of Page